PMID- 29479370
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240315
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2017
DP  - 2017
TI  - Wushenziye Formula Improves Skeletal Muscle Insulin Resistance in Type 2 Diabetes 
      Mellitus via PTP1B-IRS1-Akt-GLUT4 Signaling Pathway.
PG  - 4393529
LID - 10.1155/2017/4393529 [doi]
LID - 4393529
AB  - Background. Wushenziye formula (WSZYF) is an effective traditional Chinese 
      medicine in the treatment of type 2 diabetes mellitus (T2DM). Aim. This study 
      aimed to identify the effects and underlying mechanisms of WSZYF on improving 
      skeletal muscle insulin resistance in T2DM. Methods. An animal model of T2DM was 
      induced by Goto-Kakizaki diabetes prone rats fed with high fat and sugar for 4 
      weeks. Insulin resistance model was induced in skeletal muscle cell. Results. In 
      vivo, WSZYF improved general conditions and decreased significantly fasting blood 
      glucose, glycosylated serum protein, glycosylated hemoglobin, insulin 
      concentration, and insulin resistance index of T2DM rats. In vitro, WSZYF 
      enhanced glucose consumption in insulin resistance model of skeletal muscle cell. 
      Furthermore, WSZYF affected the expressions of molecules in regulating T2DM, 
      including increasing the expressions of p-IRS1, p-Akt, and GLUT4, reducing PTP1B 
      expression. Conclusion. These findings displayed the potential of WSZYF as a new 
      drug candidate in the treatment of T2DM and the antidiabetic mechanism of WSZYF 
      is probably mediated through modulating the PTP1B-IRS1-Akt-GLUT4 signaling 
      pathway.
FAU - Tian, Chunyu
AU  - Tian C
AUID- ORCID: 0000-0001-6234-9388
AD  - North China University of Science and Technology, Tangshan 063210, China.
AD  - Pharmacology Analysis Key Laboratory for Prevention and Treatment of Diabetes of 
      Traditional Chinese Medicine in Hebei Province, Tangshan 063210, China.
FAU - Chang, Hong
AU  - Chang H
AUID- ORCID: 0000-0002-6926-8895
AD  - North China University of Science and Technology, Tangshan 063210, China.
AD  - Pharmacology Analysis Key Laboratory for Prevention and Treatment of Diabetes of 
      Traditional Chinese Medicine in Hebei Province, Tangshan 063210, China.
FAU - La, Xiaojin
AU  - La X
AD  - North China University of Science and Technology, Tangshan 063210, China.
AD  - Pharmacology Analysis Key Laboratory for Prevention and Treatment of Diabetes of 
      Traditional Chinese Medicine in Hebei Province, Tangshan 063210, China.
FAU - Li, Ji-An
AU  - Li JA
AD  - North China University of Science and Technology, Tangshan 063210, China.
AD  - Pharmacology Analysis Key Laboratory for Prevention and Treatment of Diabetes of 
      Traditional Chinese Medicine in Hebei Province, Tangshan 063210, China.
LA  - eng
PT  - Journal Article
DEP - 20171231
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC5804399
EDAT- 2018/02/27 06:00
MHDA- 2018/02/27 06:01
PMCR- 2017/12/31
CRDT- 2018/02/27 06:00
PHST- 2017/09/08 00:00 [received]
PHST- 2017/11/25 00:00 [revised]
PHST- 2017/12/04 00:00 [accepted]
PHST- 2018/02/27 06:00 [entrez]
PHST- 2018/02/27 06:00 [pubmed]
PHST- 2018/02/27 06:01 [medline]
PHST- 2017/12/31 00:00 [pmc-release]
AID - 10.1155/2017/4393529 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2017;2017:4393529. doi: 10.1155/2017/4393529. 
      Epub 2017 Dec 31.